ImmunityBio
Corporate brand
UnclaimedImmunityBio is a biotech company developing immunotherapies that activate both innate and adaptive immune responses to treat cancer and infectious diseases.
Last updated September 11, 2026
AI crawler reads
No AI crawler has read this profile yet.
Overview
ImmunityBio is a biotech company founded in 2014. Its major focus is the development of novel treatments for advanced cancers and infectious diseases, and it is developing immunotherapies that activate both innate and adaptive immune responses. Dr. Patrick Soon-Shiong serves as Executive Chairman and Global Chief Scientific and Medical Officer.
History
ImmunityBio was founded in 2014 to create innovative therapies. Over the last two decades, Executive Chairman and Global Chief Scientific and Medical Officer Dr. Patrick Soon-Shiong has investigated mechanisms to activate the immune system to attack tumors that can otherwise evade and escape the body's defense mechanisms. After inventing the world's first protein nanoparticle drug, Abraxane, Dr. Soon-Shiong turned his focus to the next-generation of immunotherapies.
Recent events
Reported
ImmunityBio appoints two board members[4]
ImmunityBio appointed Linda Maxwell as an independent board member and appointed CEO Richard Adcock to its board, with both appointments effective March 29, 2021.
Reported
Two ImmunityBio directors conclude board service[4]
ImmunityBio said directors Fred Driscoll and John D. Thomas would conclude their board service effective with the new appointments on March 29, 2021.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/immunitybio · Editorial policy · How profiles are compiled